TEL-AML_1阳性儿童急性淋巴细胞白血病近期疗效分析

Study of the childhood acute lymphoblastic leukemia with TEL-AML_1

目的探讨TEL-AML1融合基因阳性儿童急性淋巴细胞白血病(ALL)的临床和预后特征。方法应用RT-PCR技术,对213例初诊ALL患儿骨髓进行t(12;21)染色体检测和TEL-AML1融合基因检测。结果213例ALL中25例(11.7%)存在t(12;21)染色体改变和TEL-AML1融合基因阳性,25例患儿发病时平均年龄5.8岁(2～10岁),均为非T细胞系免疫表型,以普通型ALL为主,经诱导化疗后全部得到完全缓解。结论t(12;21)/TEL-AML1表达是儿童ALL较为常见的遗传学改变,该类型儿童ALL经化疗预后良好。

Objective To explore the incidence, clinical characteristics and prognosis of childhood acute lym- phoblastic leukemia （ALL） with TEL-AML1 fusion gene. Methods t （12; 21） TEL-AML1 fusion gene was examined in bone marrow from 213 newly diagnosed childhood ALL patients by nested reverse transcriptase-polymerase chain reaction. Results t （12; 21） TEL-AML1 fusion gene was found in 25 patients, accounting for 11.7% of total 213 patients. The median age at diagnosis was 5.8 （2 to 10） years. All patients with TEL-AML1 fusion gene expressed non-T lineage immunophenotype, most of them were common-ALL, and all of them obtained complete remission after treatment. Conclu- sions t （12; 21） was the most common chromosomal translocation in childhood ALL. Patients with t （12; 21） TEL- AML1 fusion gene showed non-T cell immunotypes and most of them were CD10＋. There was no significant difference in short term outcome between patients with and without TEL-AML1.